InvestorsHub Logo
Followers 6
Posts 122
Boards Moderated 0
Alias Born 01/19/2024

Re: None

Wednesday, 05/29/2024 9:10:58 AM

Wednesday, May 29, 2024 9:10:58 AM

Post# of 48498
“the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study in order to determine the safety and efficacy of CX1739, its lead clinical AMPAkine, to improve bladder function and motor activity in individuals with spinal cord injury (SCI).”

https://www.globenewswire.com/news-release/2024/05/29/2889855/0/en/RespireRx-Pharmaceuticals-Inc-Announces-a-Department-of-Defense-Award-to-Fund-a-Phase-2-Clinical-Study-to-Determine-the-Safety-and-Efficacy-of-CX1739-its-Lead-AMPAkine-to-Improve-B.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News